70,000-share PAVmed (PAVM) restricted stock grant to CMO

Rhea-AI Filing Summary

Lee Victoria Tou-ho reported acquisition or exercise transactions in this Form 4 filing.

PAVmed Inc. reported that Chief Medical Officer Lee Victoria Tou-ho received a grant of 70,000 shares of common stock as an equity award. The restricted stock was granted at $0.00 per share and increases her direct holdings to 71,666 shares.

The award consists of restricted stock under PAVmed’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan and has a single vesting date of May 20, 2029. The shares are subject to forfeiture if the required service period is not completed, tying the grant to long-term employment and performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Lee Victoria Tou-ho

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	70,000	$0.00	--

Holdings After Transaction: Common Stock — 71,666 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock grant: 70,000 shares Grant price: $0.00 per share Shares held after grant: 71,666 shares +1 more

4 metrics

Restricted stock grant 70,000 shares Common stock award to Chief Medical Officer

Grant price $0.00 per share Price for restricted stock award

Shares held after grant 71,666 shares Direct holdings following the transaction

Vesting date May 20, 2029 Single vesting date for restricted stock

Key Terms

restricted stock, Long-Term Incentive Equity Plan, vesting date, forfeiture

4 terms

restricted stock financial

"Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

Long-Term Incentive Equity Plan financial

"under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan"

vesting date financial

"with a single vesting date of May 20, 2029"

forfeiture financial

"Such restricted stock is subject to forfeiture if the requisite service period is not completed"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Victoria Tou-ho

(Last) (First) (Middle)

360 MADISON AVENUE

25TH FLOOR

(Street)

NEW YORK NEW YORK 10017

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PAVmed Inc. [ PAVM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/02/2026		A		70,000(1)	A	$0(1)	71,666	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

	/s/ Michael A. Gordon, by power of attorney	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did PAVmed (PAVM) disclose about Chief Medical Officer Lee Victoria Tou-ho?

PAVmed disclosed that Chief Medical Officer Lee Victoria Tou-ho received a grant of 70,000 shares of restricted common stock. The award was granted at $0.00 per share and is tied to continued service with a single vesting date in May 2029.

How many PAVmed (PAVM) shares were granted to the Chief Medical Officer?

The Chief Medical Officer received a grant of 70,000 shares of PAVmed common stock as restricted stock. This equity award was issued at $0.00 per share and forms part of her long-term incentive compensation under the company’s 2014 equity plan.

When do the newly granted PAVmed (PAVM) restricted shares vest?

The 70,000 restricted shares granted to PAVmed’s Chief Medical Officer have a single vesting date of May 20, 2029. Vesting depends on completing the requisite service period, aligning the award with long-term employment and performance incentives.

Are the PAVmed (PAVM) restricted shares subject to forfeiture?

Yes. The 70,000 restricted shares granted to the Chief Medical Officer are subject to forfeiture if the requisite service period is not completed. This condition helps ensure the equity award is earned over time through continued service to the company.

How many PAVmed (PAVM) shares does the Chief Medical Officer hold after this grant?

After the grant, Chief Medical Officer Lee Victoria Tou-ho directly holds 71,666 shares of PAVmed common stock. This figure reflects her ownership following the award of 70,000 restricted shares under the company’s long-term incentive equity plan.

What compensation plan governs the PAVmed (PAVM) restricted stock grant?

The restricted stock grant to PAVmed’s Chief Medical Officer was made under the company’s Seventh Amended and Restated 2014 Long-Term Incentive Equity Plan. This plan provides equity-based awards designed to align executive compensation with long-term company performance.